Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Intensity Therapeutics, Inc. ( (INTS) ).
On July 17, 2025, Intensity Therapeutics, Inc. conducted its annual stockholders’ meeting via webcast, where 59.73% of the company’s outstanding common stock shares were represented. During the meeting, stockholders voted on two key proposals: the election of Mark A. Goldberg as a Class II director until 2028, and the ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (INTS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Average Trading Volume: 2,105,958
Technical Sentiment Signal: Sell
See more data about INTS stock on TipRanks’ Stock Analysis page.